The Framingham Heart Study (FHS) is a prospective, community-based 3-generational study that enrolled participants between ages 20-50 and has examined them every 2-4 years to collect extensive lifestyle, vascular, biomarker data; 9300 have GWAS. Embedded in this cohort are 1036 multigenerational families. Surveillance for AD dementia (and MCI) has been ongoing for over 4 decades. We have identified 1421 incident AD, 1767 MCI, enrolled 800+ in a brain donation program, obtained 7000+ 1.5T brain MRI, and repeated, detailed neuropsychological assessments. We have recently obtained extensive omics in ~6000 (gene expression, methylation, miRNA, metabolomics and proteomics) and genomics (50X whole genome sequences [WGS] in 4197 with pedigree-based imputation to 6554) through the NHLBI funded SABRe CVD (omics) and TOPMed (WGS) programs. We seek to leverage these rich resources (>$25 million). We propose these specific aims:
AIM 1 is to examine and explain temporal trends in clinical AD dementia in the FHS cohorts. The age-specific incidence of dementia has declined over the past 4 decades among FHS participants (in press). However, the reasons for this decline remain unclear. We thus propose to continue tracking temporal trends in AD dementia and MCI through intensive surveillance, and verifying diagnoses at autopsy. We hypothesize that better education, treatment of some vascular factors and protective lifestyle changes (diet, activity, social engagement) may partially explain these trends.
AIM 2 is to identify the patterns and predictors of preclinical AD within FHS families by obtaining (i) a novel circulating biomarker (plasma tau on 8000+ persons, using samples collected 5-15 years ago and repeat assay in 450) to supplement 1000+ biomarkers already available, and (ii) brain imaging with tau- and amyloid- PET, 3TMRI, including assessment of functional connectivity, tractography and blood flow, in 450 dementia- and stroke-free, FHS participants age 35-75 on whom we have (a) directly verified familial cognition and AD dementia status (both parents and all 4 grandparents were FHS participants), and also (b) have WGS and omics data.
AIM 3 is to utilize the available WGS and extensive `omics' data for deep molecular phenotyping of AD. We will undertake conventional family-based WGS analyses of AD dementia and preclinical AD endophenotypes and novel high dimensional (co-expression, network, systems-based) analyses in collaboration with Drs. DeJager (PI of Accelerated Medicine Partnerships-AD, with omics data in 1200 brains), Witten (award-winning mathematician in applying graphical analysis to omics) and Levy (PI of SABRe-CVD at FHS). We will validate our findings in unrelated and multi-ethnic (Omni) FHS participants, through collaborations with other cohorts, and share all data through dbGaP and BioLINCC for analyses by others. We expect to identify new biologic pathways, drug targets and biomarkers for AD, especially those applicable to the preclinical stage of AD and those explaining promising trends in AD risk; such pathways should prove most useful for AD prevention.

Public Health Relevance

Whereas the total number of persons with Alzheimer disease (AD) is increasing as the population ages, we have 4 decades of Framingham data suggesting that the risk at any given age is declining. We plan to study the reasons for this hopeful trend in detail through continuing our surveillance for dementia and cognitive impairment, collecting cutting edge brain imaging (amyloid and tau-PET, volumes, connectivity and perfusion on MRI) in the dementia-free (preclinical AD), and using sophisticated analysis of very extensive genetic and omic data already collected on Framingham subjects. This could help us better understand AD trends and biology and identify new biomarkers and treatment targets.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG054076-01
Application #
9194741
Study Section
Special Emphasis Panel (ZRG1-PSE-P (59)R)
Program Officer
Miller, Marilyn
Project Start
2016-09-01
Project End
2021-05-31
Budget Start
2016-09-01
Budget End
2017-05-31
Support Year
1
Fiscal Year
2016
Total Cost
$2,322,345
Indirect Cost
$214,120
Name
Boston University
Department
Neurology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Romero, José R; Beiser, Alexa; Himali, Jayandra J et al. (2017) Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study. Neurobiol Aging 54:94-99
Mattos, Meghan K; Snitz, Beth E; Lingler, Jennifer H et al. (2017) Older Rural- and Urban-Dwelling Appalachian Adults With Mild Cognitive Impairment. J Rural Health 33:208-216
Lin, Honghuang; Satizabal, Claudia; Xie, Zhijun et al. (2017) Whole blood gene expression and white matter Hyperintensities. Mol Neurodegener 12:67
Pase, Matthew P; Himali, Jayandra J; Beiser, Alexa S et al. (2017) Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study. Stroke 48:1139-1146
Desikan, Rahul S; Fan, Chun Chieh; Wang, Yunpeng et al. (2017) Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Med 14:e1002258
Saber, Hamidreza; Himali, Jayandra J; Beiser, Alexa S et al. (2017) Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study. Stroke 48:1760-1765
Pase, Matthew P; Satizabal, Claudia L; Seshadri, Sudha (2017) Role of Improved Vascular Health in the Declining Incidence of Dementia. Stroke 48:2013-2020
Chibnik, Lori B; Wolters, Frank J; Bäckman, Kristoffer et al. (2017) Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. Eur J Epidemiol 32:931-938
Dufouil, Carole; Beiser, Alexa; McLure, Leslie A et al. (2017) Revised Framingham Stroke Risk Profile to Reflect Temporal Trends. Circulation 135:1145-1159
Maillard, Pauline; Mitchell, Gary F; Himali, Jayandra J et al. (2017) Aortic Stiffness, Increased White Matter Free Water, and Altered Microstructural Integrity: A Continuum of Injury. Stroke 48:1567-1573

Showing the most recent 10 out of 52 publications